by Peter Ciszewski | Dec 11, 2020
John Hayslip, MD, executive medical director at AbbVie Pharmaceuticals discusses the latest data from the MURANO study presented at ASH 2020. The MURANO study compared the safety and efficacy of 6 months of treatment with venetoclax plus rituximab vs...
by Peter Ciszewski | Dec 10, 2020
Lawrence S. Kirschner, MD, PhD, Professor of Medicine, Division of Endocrinology, Diabetes, and Metabolism, and Director, CAMELOT (Cancer Research Training and Education), OSU Comprehensive Cancer Center provides an overview of Acromegaly, including signs and symptoms...
by Peter Ciszewski | Dec 10, 2020
Thierry Facon, MD, of Centre Hospitalier Universitaire (CHU) Lille discusses the latest results from the TOURMALINE-MM2 study presented at ASH 2020. TOURMALINE-MM2 is a phase 3 clinical trial that compared oral ixazomib, lenalidomide, and dexamethasone to...
by Peter Ciszewski | Dec 10, 2020
Andrew Kuykendall, MD, from the Moffitt Cancer Center discusses updated data of an ongoing Phase II clinical trial assessing the safety and efficacy of PTG-300 to treat individuals with polycythemia vera. The data was presented at the American Society of...
by Peter Ciszewski | Dec 9, 2020
Raymond Douglas, MD, PhD, of the Cedars-Sinai Medical Center discusses the latest clinical data with teprotumumab to treat patients with thyroid eye disease (TED). TED is a rare autoimmune disease that can dramatically impact a person’s vision. The condition...
